Pending CCG approval

NHS
Pan Mersey
Area Prescribing Committee

LUSUTROMBOPAG tablets (Mulpleo® ▼) for treating severe thrombocytopenia in adults with chronic liver disease having planned invasive procedures

The Pan Mersey Area Prescribing Committee recommends the prescribing of LUSUTROMBOPAG tablets (Mulpleo® ▼), by specialists only, for treating severe thrombocytopenia in adults with chronic liver disease having planned invasive procedures in accordance with NICE TA617

RED

NICE technology appraisal (TA) 617 recommends lusutrombopag, within its marketing authorisation, as an option for treating severe thrombocytopenia (defined as a platelet count of below 50,000 platelets per microlitre of blood) in adults with chronic liver disease having planned invasive procedures.[1]

- The recommended dose is 3 mg lusutrombopag orally once daily for 7 days.[2]
- Lusutrombopag should not be taken for more than 7 days.[2]
- The procedure should be performed from day 9 after the start of lusutrombopag treatment. Platelet count should be measured prior to the procedure.[2]

Prescribing and monitoring should be retained by either a specialist in haematology or gastroenterology, depending on the procedure.

NICE does not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations will be less than £5 million per year in England (or £9,000 per 100,000 population).

Lusutrombopag is a further treatment option and due to this, the overall incremental cost of treatment is not deemed to be significant. The addition of lusutrombopag in the treatment pathway may help reduce the need for platelet transfusions. It may also help increase the time in which procedures can be scheduled and reduce hospital stays.

References

1. National Institute for Health and Care Excellence. Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure. NICE Technology Appraisal 617, 08 January 2020. Accessed online 08 January 2020.
2. Mulpleo (previously Lusutrombopag Shinogi): EPAR – Product Information, Annex I, Summary of Product Characteristics, 10 October 2019. Accessed online 08 January 2020.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.